{"id":4051,"date":"2017-05-17T11:01:00","date_gmt":"2017-05-17T03:01:00","guid":{"rendered":"https:\/\/uni-pharma.com.tw\/shiji-and-uni-pharma-strategic-cooperation-to-seize-the-chinese-market\/"},"modified":"2025-03-13T18:28:06","modified_gmt":"2025-03-13T10:28:06","slug":"shiji-and-uni-pharma-strategic-cooperation-to-seize-the-chinese-market","status":"publish","type":"post","link":"https:\/\/uni-pharma.com.tw\/en\/shiji-and-uni-pharma-strategic-cooperation-to-seize-the-chinese-market\/","title":{"rendered":"Shiji and Uni Pharma strategic cooperation to seize the Chinese market"},"content":{"rendered":"\n

2017-05-17 19:07Economic Daily reporter Jiang Shuohan<\/a> \/ instant report<\/p>\n\n

Shiji Biomedical Co., Ltd. focuses on the product development, production and marketing of pharmacogenic and preventive medicine molecular diagnostic reagents, and in the second quarter of this year, it has strategically cooperated with Uni Pharma to obtain the exclusive sales right of Huayu colorectal cancer diagnostic reagents in mainland China, preparing to enter the precision medicine market in Chinese mainland.<\/p>\n\n

Huayu DR-70 tumor marker in vitro diagnostic reagent set is used to evaluate the early screening and postoperative follow-up of colorectal cancer, and its specificity and sensitivity are quite obvious comparedUni Pharma with other existing cancer markers.<\/p>\n\n

Huayu tumor marker detection product DR-70 is manufactured by Shiji GMP factory, has passed the review of the Food and Drug Administration of the Ministry of Health and Welfare of Taiwan, obtained the marketing license, and has successively conducted clinical trials in China’s tertiary hospitals and multiple medical centers, with a total number of more than 1,000 patients, and follow-up tracking, and is expected to obtain the marketing license of the third class III medical device in vitro inspection reagent of the China Food and Drug Administration (CFDA) in 2018.<\/p>\n\n

At this stage, Sec will use the Laboratory Self-Construction Project (LDT) to immediately launch DR-70 colorectal cancer surgery and DR-70 for early cancer detection services with qualified clinical laboratories in China, and will also build hospital laboratory access in the future.<\/p>\n\n

There are at least 400,000 new cases of colorectal cancer in China every year, and due to the lack of effective early diagnosis and postoperative screening methods, about 200,000 people die from colorectal cancer every year, ranking fifth among the number of deaths due to cancer.<\/p>\n\n

DR-70, a next-generation colorectal cancer screening test that can be used to detect fibrin degradant (FDP) in the blood, has been approved by the EU, FDA, and Taiwan TFDA.<\/p>\n\n

Clinical studies have shown that DR-70 can detect 71.6% of patients with micro-recurrence of colorectal cancer with normal CEA, and can also be used in the early screening of other cancers, such as lung cancer, stomach cancer, breast cancer, liver cancer, etc., so the product provides valuable disease detection information for the medical team, which is a great benefit to patients with early cancer.<\/p>\n\n

Huayu Pharmaceutical (6621) is a biotechnology company invested by Jianya, which has handled a public offering of shares and is expected to be listed on the stock market in August this year. The DR-70 tumor marker in vitro diagnostic reagent set is a product developed and transferred by Huayu Pharmaceutical, which has given high praise to the establishment and development of the Chinese market in the past year, and is convinced that by combining the business advantages of Globalgene in China, it can quickly develop the penetration rate of DR-70 and reach a new milestone in public health cancer prevention and control.<\/p>\n\n

Secy and Kilon Meeks (4195) both belong to Kimi Group, and Secy will continue to develop and introduce innovative products in the fields of precision medicine such as pharmacogenetic diagnosis, preventive medicine and early diagnosis of diseases, so as to increase product advantages and expand revenue.<\/p>\n\n

Founded in 2005, Worldwide Biomedicine focuses on the development, production and marketing of pharmacogenetic and preventive medicine molecular diagnostic reagent products, has more than 100 genetic testing patents in many countries around the world, and has applied for 14 marketing licenses for diagnostic products around the world. At the end of 2015, it obtained two marketing licenses for pharmacogenetic diagnosis from the China Food and Drug Administration, and established a sales channel in China in 2016, successfully selling 35,000 reagents.<\/p>\n\n

\"172455486488714
GlobalBiomed grabbed China’s precision medicine market and obtained the exclusive right to sell Huayu colorectal cancer diagnostic reagents, the photo shows Huang Zhaoxi (right), chairman of GlobalBiomedical. Photo \/ provided by Shiji.<\/figcaption><\/figure>\n\n
\"172455486440046
GlobalBiomed grabbed China’s precision medicine market and obtained the exclusive right to sell Huayu colorectal cancer diagnostic reagents, the photo shows Huang Zhaoxi (right), chairman of GlobalBiomedical. Photo \/ provided by Shiji.<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"

2017-05-17 19:07Economic Daily reporter Jiang Shuohan \/ instant report Shiji Biomedical Co., Ltd. focuses on the product development, production and marketing of pharmacogenic and preventive medicine molecular diagnostic reagents, and in the second quarter of this year, it has strategically cooperated with Uni Pharma to obtain the exclusive sales right of Huayu colorectal cancer diagnostic […]<\/p>\n","protected":false},"author":1,"featured_media":3344,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[187,188],"tags":[],"class_list":["post-4051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-whats-new","category-industry-news"],"blocksy_meta":[],"acf":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/uni-pharma.com.tw\/wp-content\/uploads\/2023\/12\/cover-default-1.jpg?fit=1000%2C800&ssl=1","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgrulY-13l","_links":{"self":[{"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/posts\/4051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/comments?post=4051"}],"version-history":[{"count":2,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/posts\/4051\/revisions"}],"predecessor-version":[{"id":4055,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/posts\/4051\/revisions\/4055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/media\/3344"}],"wp:attachment":[{"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/media?parent=4051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/categories?post=4051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/uni-pharma.com.tw\/en\/wp-json\/wp\/v2\/tags?post=4051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}